TY - JOUR
T1 - Analysis of 130 Cases of Sympathetic Ophthalmia–A Retrospective Multicenter Case Series
AU - Tan, Xiu Ling
AU - Seen, Sophia
AU - Dutta Majumder, Parthopratim
AU - Ganesh, Sudha K.
AU - Agarwal, Mamta
AU - Soni, Aniruddh
AU - Biswas, Jyotirmay
AU - Aggarwal, Kanika
AU - Mahendradas, Padmamalini
AU - Gupta, Vishali
AU - Ling, Ho Su
AU - Teoh, Stephen
AU - Pavesio, Carlos
AU - Agrawal, Rupesh
N1 - Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.
PY - 2019/11/17
Y1 - 2019/11/17
N2 - Objective: To analyze the demographic profile, treatment, and visual outcome of the patients with sympathetic ophthalmia (SO) in a multicenter collaborative retrospective cohort study. Methods: Medical records of the patients with SO from UK, Singapore, India were reviewed for history of ocular trauma or surgery and subsequent development of uveitis consistent with SO, presenting symptoms, treatment, and visual outcomes. Results: A total of 130 patients were diagnosed with SO during the study period. Eighty-one (62.3%) patients were men. The mean age was 48.4 ± 15.5 years. The most common presenting symptom was blurring of vision (89.2%), followed by pain (29.2%) and floaters (23.8%). Ninety-two (70.7%) required additional immunosuppressive therapy. Thirty-six (27.9%) patients underwent enucleation of the inciting eye. Conclusions: SO is a potentially sight-threatening disease with high rates of visual loss. It warrants prompt evaluation and treatment. With the advances and availability in immunotherapy, the visual prognosis is relatively good.
AB - Objective: To analyze the demographic profile, treatment, and visual outcome of the patients with sympathetic ophthalmia (SO) in a multicenter collaborative retrospective cohort study. Methods: Medical records of the patients with SO from UK, Singapore, India were reviewed for history of ocular trauma or surgery and subsequent development of uveitis consistent with SO, presenting symptoms, treatment, and visual outcomes. Results: A total of 130 patients were diagnosed with SO during the study period. Eighty-one (62.3%) patients were men. The mean age was 48.4 ± 15.5 years. The most common presenting symptom was blurring of vision (89.2%), followed by pain (29.2%) and floaters (23.8%). Ninety-two (70.7%) required additional immunosuppressive therapy. Thirty-six (27.9%) patients underwent enucleation of the inciting eye. Conclusions: SO is a potentially sight-threatening disease with high rates of visual loss. It warrants prompt evaluation and treatment. With the advances and availability in immunotherapy, the visual prognosis is relatively good.
KW - Corticosteroids
KW - enucleation
KW - immunosuppressive therapy
KW - phthisis bulbi
KW - sympathetic ophthalmia
KW - trauma
UR - http://www.scopus.com/inward/record.url?scp=85053471088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053471088&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1517894
DO - 10.1080/09273948.2018.1517894
M3 - Article
C2 - 30207811
AN - SCOPUS:85053471088
SN - 0927-3948
VL - 27
SP - 1259
EP - 1266
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 8
ER -